Periodic Safety Update Reports Compliance Services

A periodic safety update report, or PSUR, is a formal post-market surveillance document required under EU MDR for certain medical devices. It summarizes complaint data, vigilance events, trend analysis, corrective actions, sales or usage information, and the current benefit-risk determination. The report shows regulators and Notified Bodies that the manufacturer is actively monitoring device safety and performance after market placement.

Under EU MDR, manufacturers of Class IIb and Class III medical devices are generally required to prepare PSURs, while Class IIa devices typically require a post-market surveillance report instead. The exact obligation depends on device classification, market status, and applicable regulatory pathways. Manufacturers must ensure the report is updated at the required frequency and made available to the relevant authorities or Notified Body.

A PSUR should include the conclusions of the benefit-risk determination, main findings from post-market surveillance data, complaint and vigilance summaries, trend reporting outcomes, CAPA-related insights, and relevant sales or population exposure data. It should also explain any preventive or corrective actions taken. The content must be consistent with your PMS plan, risk management file, and clinical evaluation documentation.

For Class III and implantable devices, PSURs are generally updated at least annually. For Class IIb devices, the frequency is typically at least every two years unless a different interval is justified by the applicable requirements. Manufacturers should confirm the reporting cadence based on device classification, certification status, and Notified Body expectations, then maintain a documented schedule to avoid missed compliance deadlines.

A PMS report is usually prepared for Class I and Class IIa devices and provides a summary of post-market surveillance findings. A PSUR is more detailed and is required for higher-risk devices, especially Class IIb and Class III. It includes deeper analysis of safety and performance data, benefit-risk conclusions, and a stronger linkage to vigilance, CAPA, and risk management activities.

Common issues include incomplete complaint trending, weak linkage between PMS findings and risk files, outdated benefit-risk assessments, inconsistent data across quality records, and reports that simply summarize events without meaningful analysis. Another frequent problem is treating the PSUR as a standalone document instead of integrating it with CAPA, clinical evaluation, vigilance reporting, and post-market governance processes required under EU MDR.

Yes. Elexes can review your existing complaint records, PMS outputs, reportability decisions, and supporting quality documentation to identify gaps before PSUR drafting begins. The team helps structure the data, improve traceability, and align findings with risk management and clinical records. This makes the final report more coherent, more defensible, and easier to support during audits or Notified Body review.

PSURs are primarily an EU MDR obligation, but the underlying work often overlaps with broader global post-market compliance activities. Complaint handling, vigilance assessment, trend analysis, CAPA linkage, and risk file updates also support FDA, TGA, Health Canada, and other regulatory expectations. A well-managed PSUR process can therefore strengthen your overall post-market governance, not just your EU documentation.